Avastin biosimilar "Onbevezy" can be prescribed in earnest
By Eo, Yun-Ho | translator Choi HeeYoung
22.01.20 17:07:37
가나다라
0
After three months of insurance benefit registration, it passed D.C. through medical institutions such as Samsung, Seoul National University, and AMC
Expect synergy through collaboration with Boryung, it is predicted that competition will expand by joining generics
According to related industries, Onbevezy, a biosimilar of the blockbuster anticancer drug Avastin, passed DC of medical institutions such as Chilgok Kyungpook National University Hospital and Hwasun Chonnam National University Hospital, including Samsung Medical Center, Seoul National University Hospital, and Asan Medical Center.
It has been entering the market quickly since insurance benefits were registered in September last year. Onbevezy's price was set at 208,144 won for 0.1g/4ml and 677,471 won for 0.4g/16ml. Compared to the original Avastin, it is 69% and 63%, respectively. Boryung Pharm
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)